常染色体显性多囊肾病中白蛋白尿与托伐普坦:TEMPO 3:4 试验结果
本文为TEMPO 3:4试验的事后分析,纳入1375例常染色体显性多囊肾病(ADPKD)患者,将白蛋白尿作为连续变量分析托伐普坦的影响。结果显示基线白蛋白尿越高,eGFR下降越快;托伐普坦组白蛋白尿较安慰剂组降低,第36个月差异最大为24%(P < 0.001),且不依赖血压。
要点
- 基线白蛋白尿越高,ADPKD患者eGFR下降越快(趋势P < 0.0001)。
- 托伐普坦组白蛋白尿较安慰剂组降低,第36个月差异最大为24%(P < 0.001)。
- 托伐普坦对白蛋白尿的降低不依赖血压,且在各亚组中相似。
核心结论
- 在ADPKD中,基线白蛋白尿越高与更多eGFR丢失相关。
- 托伐普坦较安慰剂降低白蛋白尿,且不依赖血压。
- 托伐普坦对TKV增长和eGFR丢失的疗效在基线白蛋白尿较高的患者中更易被检测到。
研究设计与样本
- TEMPO 3:4试验的事后分析,为为期3年前瞻性、盲法随机对照试验,纳入1375例ADPKD患者。
主要发现
- 基线ACR中位数(四分位距)为3.2(1.7-7.1)mg/mmol;47.9%的患者ACR正常,48.7%中度升高,3.4%重度升高。
- 基线ACR较高的受试者血压和总肾脏体积(TKV)较高,估算肾小球滤过率(eGFR)较低。
- 随访期间,基线ACR越高与eGFR丢失越快相关(趋势P < 0.0001),但与TKV增长率无关。
- 3年试验期间,ACR在安慰剂组升高、在托伐普坦组降低(+0.23 vs -0.40 mg/mmol)。
- ACR差异随时间增大,第36个月达到最大24%(P < 0.001);此时血压仅见微小差异(托伐普坦组平均动脉压-1.9 mmHg)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The TEMPO 3:4 Trial results suggested that tolvaptan had no effect compared with placebo on albuminuria in autosomal-dominant polycystic kidney disease (ADPKD) patients. However, the use of categorical 'albuminuria events' may have resulted in a loss of sensitivity to detect changes. The aim of this study is to investigate the effects of tolvaptan on albuminuria as a continuous variable. METHODS: Post hoc analysis of a 3-year prospective, blinded randomized controlled trial, including 1375 ADPKD patients. Albuminuria was measured in a spot morning urine sample prior to tolvaptan dosing and expressed as albumin-to-creatinine ratio (ACR). RESULTS: Baseline median (interquartile range) ACR was 3.2 (1.7-7.1) mg/mmol. Of note, 47.9% of ADPKD patients had normal, 48.7% moderately increased and 3.4% severely increased ACR. Subjects with higher baseline ACR had higher blood pressure and total kidney volume (TKV) and lower estimated glomerular filtration rate (eGFR). During follow-up, higher baseline ACR was associated with more rapid eGFR loss (P < 0.0001 for trend), but not with rate of growth in TKV. During the 3-year trial, ACR rose in placebo- and decreased in tolvaptan-treated patients (+0.23 versus -0.40 mg/mmol). The difference ACR increased over time, reaching a maximum of 24% at Month 36 (P < 0.001). At that time only a minor difference in blood pressure was observed (mean arterial pressure -1.9 mmHg for tolvaptan). The decrease in ACR was similar in all subgroups investigated, and remained after withdrawal of study drug. The beneficial effect of tolvaptan on TKV growth and eGFR loss was stronger in patients with higher baseline ACR. CONCLUSIONS: In ADPKD, higher baseline albuminuria was associated with more eGFR loss. Tolvaptan decreased albuminuria compared with placebo, independent of blood pressure. Treatment efficacy of tolvaptan on changes in TKV and eGFR was more readily detected in patients with higher albuminuria.
引用
- Gansevoort RT, Meijer E, Chapman AB, et al. Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: results of the TEMPO 3:4 Trial. Nephrol Dial Transplant. 2015. PMID: 26681730
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。